Navigation Links
Cephalon, Inc. to Webcast Analyst Day
Date:10/30/2008

FRAZER, Pa., Oct. 30 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) today announced that its Analyst Day in New York City, to be held on November 5, 2008, will be webcast live on the investor relations section of its website at http://www.cephalon.com.

Cephalon's senior management will review the company's business strategy, marketing plan and research and development initiatives. The presentations will be delivered on Wednesday, November 5, 2008 beginning at approximately 12:30 p.m. EST and ending at 3:15 p.m. EST. The webcast will be archived for one week following the broadcast. To access the webcast, log on to the company's website at http://www.cephalon.com and click on "Investors," then "Webcast." Click on the link and follow the prompts for registration and access.

About Cephalon, Inc.

Founded in 1987, Cephalon, Inc. is an international biopharmaceutical company dedicated to the discovery, development and commercialization of innovative products in four core therapeutic areas: central nervous system, pain, oncology and addiction. A member of the Fortune 1000, Cephalon currently employs approximately 3,000 people in the United States and Europe. U.S. sites include the company's headquarters in Frazer, Pennsylvania, and offices, laboratories or manufacturing facilities in West Chester, Pennsylvania, Salt Lake City, Utah, and suburban Minneapolis, Minnesota. The company's European headquarters are located in Maisons-Alfort, France.

The company's proprietary products in the United States include: TREANDA(R) (bendamustine hydrochloride) for Injection, AMRIX(R) (cyclobenzaprine hydrochloride extended-release capsules), PROVIGIL(R) (modafinil) Tablets [C-IV], FENTORA(R) (fentanyl buccal tablet) [CII], TRISENOX(R) (arsenic trioxide) injection, VIVITROL(R) (naltrexone for extended-release injectable suspension), GABITRIL(R) (tiagabine hydrochloride), NUVIGIL(TM) (armodafinil) Tablets [C-IV] and ACTIQ(R) (oral transmucosal fentanyl citrate) [C-II]. The company also markets numerous products internationally. Full prescribing information on its U.S. products is available at http://www.cephalon.com or by calling 1-800-896-5855.

In addition to historical facts or statements of current condition, this press release may contain forward-looking statements. Forward-looking statements provide Cephalon's current expectations or forecasts of future events. These may include statements regarding anticipated scientific progress on its research programs; development of potential pharmaceutical products; interpretation of clinical results; prospects for regulatory approval; manufacturing development and capabilities; market prospects for its products; sales, adjusted net income and basic adjusted income per common share guidance; and other statements regarding matters that are not historical facts. You may identify some of these forward-looking statements by the use of words in the statements such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe" or other words and terms of similar meaning. Cephalon's performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, regulatory and political conditions affecting the biotechnology and pharmaceutical industries as well as more specific risks and uncertainties facing Cephalon such as those set forth in its reports on Form 8-K, 10-Q and 10-K filed with the U.S. Securities and Exchange Commission. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward- looking statements. Furthermore, Cephalon does not intend to update publicly any forward-looking statement, except as required by law. The Private Securities Litigation Reform Act of 1995 permits this discussion.


'/>"/>
SOURCE Cephalon, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Cephalon, Inc. Announces Agreement to Acquire AMRIX, A Once-Daily Extended-Release Muscle Relaxant
2. Anesiva to Host Conference Call and Webcast Tomorrow to Discuss Encouraging Development in Zingo(TM) Program
3. Caliper Life Sciences Presentation at Thomas Weisel Partners Healthcare Conference to be Webcast
4. Thomas Weisel Partners 2007 Healthcare Conference To Webcast Millennium Presentation
5. deCODE genetics to Webcast Presentation at Thomas Weisel Partners Annual Healthcare Conference
6. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Thomas Weisel Partners Conference
7. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at BioCentury-Thomson Financial Investment Conference
8. Volcano Corporation Presentation at Bear Stearns Conference to be Webcast
9. Telik Announces Presentation and Webcast at Bear Stearns Healthcare Conference
10. ZymoGenetics to Webcast Presentation at Two Upcoming Conferences
11. MIGENIX First Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... 2016 Q BioMed Inc. ... CEO  was featured in an article he wrote ... Fear To Tread: http://www.lifescienceleader.com/doc/accelerators-enter-when-vcs-fear-to-tread-0001 ... is an essential business journal for life science ... to Big Pharmas. Their content is designed to ...
(Date:4/27/2016)... ... April 27, 2016 , ... Cambridge Semantics, the leading provider ... announced that it has been named to The Silicon Review’s “20 Fastest Growing Big ... markets, Cambridge Semantics serves the needs of end users facing some of the most ...
(Date:4/27/2016)... and RESEARCH TRIANGLE PARK, N.C. ... (NASDAQ: UTHR ) announced today that ... of United Therapeutics will provide an overview and update ... st Annual Health Care Conference. The ... at 10:00 a.m. Eastern Time, and can be accessed ...
(Date:4/27/2016)... ... ... Global Stem Cells Group CEO Benito Novas announced that Duncan ... affiliate Kimera Labs in Miami. , In 2004, Ross received his Ph.D. in Immunology ... disorders and the suppression of graft vs. host disease (GVHD) under UM Professor Robert ...
Breaking Biology Technology:
(Date:3/15/2016)... 15, 2016 --> ... Transparency Market Research "Digital Door Lock Systems Market - Global ... 2023," the global digital door lock systems market in terms ... and is forecast to grow at a CAGR of 31.8% ... and medium enterprises (MSMEs) across the world and high industrial ...
(Date:3/14/2016)... , March 14, 2016 NXTD ... growing mobile commerce market, announces the airing of a new ... starting the week of March 21 st .  The commercials ... including its popular Squawk on the Street show. --> ... on the growing mobile commerce market, announces the airing of ...
(Date:3/11/2016)... http://www.apimages.com ) - --> http://www.apimages.com ) - ... Images ( http://www.apimages.com ) - Germany . ... new refugee identity cards. DERMALOG will be unveiling this device, and ... Hanover next week.   --> Germany ... the new refugee identity cards. DERMALOG will be unveiling this device, ...
Breaking Biology News(10 mins):